Navigation Links
CEL-SCI Corporation Announces 2007 Financial Results
Date:1/14/2008

VIENNA, Va., Jan. 14 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (Amex: CVM) reports financial results for the fiscal year ending September 30, 2007.

CEL-SCI reports a net operating loss for fiscal year 2007 of $9,352,209 versus a net operating loss of $5,349,196 in fiscal year 2006. The loss per share for fiscal year 2007 was unchanged at $(0.10) compared to fiscal year 2006.

The cash from operating activities used during the year was about $4,890,100. CEL-SCI's assets during the year grew from $9.6 million in fiscal year 2006 to $20.7 million in fiscal year 2007.

Geert Kersten, Chief Executive Officer said, "CEL-SCI had a very successful year in that it received FDA go-ahead for a Phase III clinical trial with its cancer drug Multikine, raised substantial amounts of money and began building a dedicated manufacturing facility for Multikine. We are looking forward to taking over the completed facility in 2008 and starting the global Phase III trial."

About CEL-SCI's Phase III Cancer Drug Multikine:

In Phase II clinical trials Multikine was shown to be safe and well- tolerated, and to improve the patients' overall survival by 33% at a median of three and a half years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007.

Multikine, a patented defined mixture of naturally derived cytokines, is the first immunotherapeutic agent in a new class of drugs called "Immune SIMULATORS". Immune SIMULATORS simulate the way our natural immune system acts in defending us against cancer.
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
2. CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference
3. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
4. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
5. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
6. CEL-SCI Corporation Releases Letter to Shareholders
7. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
8. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
9. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
10. Immunosyn Corporation Releases SF-1019 Study Results
11. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... MONTREAL , 21. November 2014 ... hat heute bekannt gegeben, dass ... – EMA) die Kennzeichnung als Orphan-Medizinprodukt ... Produktkandidat des Unternehmens zur Behandlung von ... eine seltene, stark beeinträchtigende genetische Krankheit, ...
(Date:11/21/2014)... 20, 2014  Edwards Lifesciences Corporation (NYSE: ... heart valves and hemodynamic monitoring, announced today that it ... support a strong launch of Edwards Lifesciences Foundation,s new ... improve the global communities where its employees live and ... giving will exceed $8 million, including more than $7 ...
(Date:11/21/2014)... BRYDGES, Ontario , Nov. 20, 2014 /PRNewswire/ ... monitor mounting solutions and reading room environment guidance, ... their newest musculoskeletal radiology reading room, which may ... room designs at Penn Medicine. ... by the American College of Radiology,s Imaging 3.0 ...
Breaking Medicine Technology:Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3Edwards Lifesciences Increases Charitable Giving In 2014 To Support Launch Of Every Heartbeat Matters 2RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 2RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 3
... TARRYTOWN, N.Y., April 18, 2012 Bayer HealthCare today ... has cleared its CONTOUR® Next EZ, a new blood ... States.  CONTOUR Next EZ includes an easy-to-use meter and ... new BGM system is being introduced on a market-by-market ...
... launches their Latching Micro-D™ connectors with a new ... quick cable connections to rack and panel equipment.  ... weight, the new latching Micro-D™ connectors, at .050" ... including pull tests that exceeds 100 pound pull ...
Cached Medicine Technology:U.S. FDA Clears Bayer HealthCare's CONTOUR® Next EZ Blood Glucose Monitoring System 2U.S. FDA Clears Bayer HealthCare's CONTOUR® Next EZ Blood Glucose Monitoring System 3Omnetics Launches Panel Mounted Latching Micro-D™ Connectors 2
(Date:11/23/2014)... SWAccessControl.com's high quality access control power suppliers are popular ... its new collection of power suppliers. Additionally, it has ... suppliers. All the new models come with big discounts, ... Dec. 20, 2014. , SWAccessControl.com has thousands of happy ... for a long time. It is very wise to ...
(Date:11/23/2014)... Church, VA (PRWEB) November 23, 2014 ... TV Have in Common, **FDAnews On-Demand Webinar**, Dec. 11, ... http://www.fdanews.com/TheFDAisWatchingOnDemand , The FDA’s focus on promotional activities ... , Now they're looking at websites, Twitter, ... Mark the calendar for Thursday, Dec. 11, for On-Demand ...
(Date:11/22/2014)... SC (PRWEB) November 23, 2014 Every ... to their communities. AlignLife experience rapid growth in the ... a very unique opportunity. AlignLife of Simpsonville ... AlignLife offices for their first annual Toy Drive. These ... charity they would support with this year's toy drive. ...
(Date:11/22/2014)... (PRWEB) November 23, 2014 A classic black ... of the most famous dress suppliers, has unveiled its new ... new dresses are now offered at a big discount, up ... special offer. , The new black prom dresses, made ... order to meet the needs of all customers, the company ...
(Date:11/22/2014)... “Due to my knee replacement surgery, I had to ... using the ice grip attachment, I noticed how dangerous the ... be a safer way to prevent possible injuries, so I ... BLOCK offers added safety and stability in slick and icy ... and damage associated with traditional spiked ice grips. As a ...
Breaking Medicine News(10 mins):Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 3Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 5Health News:Greenville Area AlignLife Offices Join Together for a Local Toy Drive 2Health News:New Black Prom Dresses from BellasDress.com 2
... , , MISSION VIEJO, Calif., Sept. ... the parent company of the Ensign(TM) group of skilled nursing, rehabilitative ... of Directors has declared a quarterly cash dividend of $0.045 per ... 2009 to shareholders of record as of September 30, 2009. Ensign ...
... BOTHELL, Wash., Sept. 18 SCOLR Pharma, Inc. ... September 15, 2009, the NYSE Amex LLC (the "Exchange") accepted ... disclosed listing deficiency as set forth in Section 1003(a)(iii) of ... Company,s failure to maintain stockholder,s equity of at least $6,000,000 ...
... , , LAWRENCE, Mass., Sept. ... leading manufacturer of innovative dialysis products, today announced that home dialysis ... Road Trip" with the NxStage(R) System One(TM). As a portable ... opportunity to fit hemodialysis therapy into his own lifestyle and schedule. ...
... , , , , ... hip abnormalities, combined with advances in diagnostic imaging techniques and minimally ... chronic, misdiagnosed hip pain. , , Increasingly, ... of degenerative hip disease, get patients back to their chosen activities ...
... , Statement of Andy Stern, President of ... Andy Stern, President of the Service Employees International Union, ... extremists to silence working families by attacking progressive individuals and community ... of profound change for this country -- from kitchen tables to ...
... , , HAYWARD, Calif., Sept. ... global leader in the medical aesthetics market, today announced that it ... on Tuesday, September 29, 2009 at the Grand Hyatt New York ... for 10:30 a.m. Eastern Time on September 29, 2009. Stephen ...
Cached Medicine News:Health News:SCOLR Pharma, Inc. Receives Notice from NYSE Amex LLC Regarding Compliance Plan and Listing Standards 2Health News:SCOLR Pharma, Inc. Receives Notice from NYSE Amex LLC Regarding Compliance Plan and Listing Standards 3Health News:SCOLR Pharma, Inc. Receives Notice from NYSE Amex LLC Regarding Compliance Plan and Listing Standards 4Health News:NxStage Patient Takes Dialysis Machine on Third Annual Patient Good-Will Tour 2Health News:NxStage Patient Takes Dialysis Machine on Third Annual Patient Good-Will Tour 3Health News:Early Diagnosis and Treatment of Hip Conditions is Focus of New Center 2Health News:Early Diagnosis and Treatment of Hip Conditions is Focus of New Center 3Health News:Early Diagnosis and Treatment of Hip Conditions is Focus of New Center 4Health News:Early Diagnosis and Treatment of Hip Conditions is Focus of New Center 5Health News:Working Women and Men Will Not Be Silenced by Right Wing Attack Dogs; SEIU Members and Other Working Americans Will Continue to Speak Out For the America We Believe In 2Health News:Solta Medical to Present at the Maxim Group Growth Conference 2
... VasoSeal VHD was the ... stop bleeding after diagnostic ... radiology procedures. It is ... device approved for immediate ...
... VasoSeal VHD was the ... stop bleeding after diagnostic ... radiology procedures. It is ... device approved for immediate ...
InterVascular HemaCarotid Patch product line offers the vascular surgeon a complete range of knitted, collagen coated patches in a wide range of sizes for carotid endarterectomy and angioplasty witho...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
Medicine Products: